Maastricht University Medical Center
Maastricht, Limburg, 6202 AZ, Netherlands
NCT Number: NCT00780819
On regular (diagnostic) MRI images brain tumors can show "contrast enhancement": uptake of an intravenously administered contrast agent can cause an enhancement pattern that is seen as a white area on a frequently used MRI protocol ("T1 weighted imaging"). High grade gliomas are a common brain tumor that share this enhancement pattern. The goal of surgery is to resect this contrast enhancing part without causing additional neurological damage. Intraoperative MRI (iMRI) is a helpful tool in achieving this goal, because it can provide updated images during resection and correct for deformations that occur in the brain during surgery. These deformations make preoperative images that are used for standard neuronavigation systems less reliable. However, due to manipulations during surgery, the contrast uptake during surgery may differ from contrast uptake in diagnostic MRI. This study aims to relate contrast enhancement on iMRI and tumor characteristics on tissue samples from the tumor. When the neurosurgeon considers the resection of the high grade glioma to be complete, an iMRI scan will be made, and tissue sampling will be performed on the borderzones of the tumor or tumor resection cavity respectively. This will provide insight in the relation between contrast enhancement on iMRI and the presence of tumor tissue. Such knowledge is important to improve effectiveness and safety of iMRI guided brain tumor resection.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Maastricht, Limburg, 6202 AZ, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
Other names: manufactured by Odin Medical Technologies (Yokneam, Israel), incorporated in Medtronic Navigation (Louisville, CO; USA)
Time frame: after surgery, and after 1 year for additional immunochemistry
Time frame: within 72 hours after surgery
Time frame: 1 week after surgery
Time frame: after 4 years
Maastricht University Medical Center
Other
Does Borderzone Contrast Enhancement on Intraoperative MRI During High Grade Glioma Resection Correlate With Residual Tumor?
Acronym: BZS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07499141
Astrocytoma, Brain Diseases
Alessandria, Italy
View Trial DetailsNCT05375318
Astrocytoma, Astrocytoma, Grade IV
Valencia, Spain
View Trial DetailsNCT04734444
Astrocytoma, Brain Diseases
Günzburg, Germany
View Trial DetailsNCT02655601
Astrocytoma, Astrocytoma, Grade III
Birmingham, Alabama, United States
View Trial Details